Drugs News and Research

RSS

FDA grants fast track designation to Synageva for SBC-102 program for Lysosomal Acid Lipase Deficiency

Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders, announced today that their lead program, SBC-102, an enzyme replacement therapy for Lysosomal Acid Lipase (LAL) Deficiency, currently in clinical trials, has been granted fast track designation by the U.S. Food and Drug Administration (FDA).

23 Jun 2011

FDA grants Fast Track designation for Repligen's RG3039 to treat Spinal Muscular Atrophy

Repligen Corporation announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for RG3039, a potential treatment for Spinal Muscular Atrophy.

23 Jun 2011

Randox Drug Residues release newly improved Multi-Sulphonamide Testing Platform

Randox Drug Residues have released their newly improved Antimicrobial Array I. This comprehensive multiplex testing platform allows for the simultaneous detection of 15 of the most commonly abused sulphonamides in food production and agricultural industries.

From Randox Laboratories Ltd. 23 Jun 2011

SNP identification may help predict patients’ susceptibility to postoperative nausea and vomiting

There are several anesthetic complications that may have a hereditary background, including postoperative nausea and vomiting (PONV). Past observations have shown PONV to occur in blood relatives as far back as two to three generations.

23 Jun 2011

Diamyd Medical to terminate US DiaPrevent Phase III study for type 1 diabetes

Diamyd Medical AB reports that the Company has decided to suspend dosing in a US Phase III study with the antigen-based therapy Diamyd and to initiate closure of the study.

23 Jun 2011

Incivek-combination therapy increases chances of HCV patients achieving viral cure

The drug Incivek, when given in combination with two other medications, can dramatically increase the chances of people chronically infected with untreated genotype 1 hepatitis C virus achieving a viral cure. That's the finding of a study published in the June 23rd issue of the New England Journal of Medicine.

23 Jun 2011

Telaprevir drug shows promise in curing hepatitis C infection

The drug telaprevir (Incivek) provides a dramatic improvement in the treatment of the most common form of hepatitis C infection, says an international team of investigators led by Dr. Ira M. Jacobson of NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

23 Jun 2011

High dose statins raise risk of diabetes: Study

According to the latest research taking a high-dose statin to lower cholesterol may increase risk of developing diabetes by as much as 12 percent, but the heart benefits of statins still outweigh the risks.

23 Jun 2011

New genetic research holds promise for patients with Chuvash polycythemia

New research conducted at UNC Lineberger Comprehensive Cancer Center, offers hope for people with a rare disorder called Chuvash polycythemia.

23 Jun 2011

India looking to supply generic drugs to Japan

After serving as "a lifeline to poor countries, supplying HIV drugs that have saved millions of lives … now India is aiming to become a drugs factory for rich countries such as Japan," which is looking to use more generic drugs in an effort to slow rising health care costs, Nature News reports.

23 Jun 2011

MUHC/McGill parasite disease researcher wins CPHA International Public Health Award

With close to one third of the world's population infected with parasitic worms, MUHC researcher Dr. Theresa Gyorkos is thinking big when it comes to finding a solution to this global public health challenge. As part of an international research and policy team, she is contributing to the soon-to-be-released WHO Strategic Plan to control intestinal worm infections in more than 100 countries.

23 Jun 2011

Marijuana or amphetamines could impair drivers and lead to fatal crashes

It-s well known that drunk driving can have fatal consequences, but a new study suggests that alcohol is not the only drug that-s a danger on the road.

23 Jun 2011

Rush scientist receives NIH grant to evaluate whether cinnamon may treat MS

A neurological scientist at Rush University Medical Center has received a grant from the National Institutes of Health (NIH) to evaluate whether cinnamon, a common food spice and flavoring material, may stop the destructive process of multiple sclerosis.

23 Jun 2011

NYSCF receives Golub family gift to launch new initiative for Parkinson's Disease

The New York Stem Cell Foundation (NYSCF) has received a half-million dollar gift from the Golub family to launch the NYCF-Golub Stem Cell Initiative for Parkinson's Disease.

23 Jun 2011

New open access journal dedicated to collaborations and cutting-edge research in parasitology

Elsevier, a world-leading provider of scientific, technical and medical information products and solutions, in association with the Australian Society for Parasitology, is pleased to announce the launch of a new journal, International Journal for Parasitology: Drugs and Drug Resistance. The new electronic open access journal is closely affiliated with the leading parasitology journal, International Journal for Parasitology, and will address a critical area of research, covering anti-parasite drug identification, development and evaluation, and parasite drug resistance. The journal's remit also includes research into natural products as anti-parasitic agents, and bioactive parasite products.

22 Jun 2011

Naurex commences GLYX-13 Phase II trial in treatment-resistant depression

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has initiated a Phase II clinical trial of its lead compound GLYX-13.

22 Jun 2011

Elsevier introduces new open-access journal on parasitology

22 Jun 2011

Sanofi, Medco and UBC to use real-world evidence for quality patient care

Sanofi, Medco Health Solutions, Inc. and its wholly owned subsidiary, United BioSource Corporation (UBC), announced they have entered into a global, multi-year agreement to support the real-world evidence assessments during Sanofi product development and pre-/post-approval processes that support improvements in the overall quality of patient care.

22 Jun 2011

UC Riverside research could lead to novel therapeutics for epileptic seizures

Researchers at the University of California, Riverside have made a discovery in the lab that could help drug manufacturers develop new antiepileptic drugs and explore novel strategies for treating seizures associated with epilepsy - a disease affecting about two million Americans.

22 Jun 2011

22nd Century submits IND to FDA for VLN cigarettes

22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction, announced today that 22nd Century Limited, LLC submitted an Investigational New Drug Application (IND) to the U.S. Food & Drug Administration (FDA) for X-22, a prescription smoking cessation aid in development.

22 Jun 2011